Cover ImageSALE
市場調查報告書

青光眼治療藥的全球市場:2017年∼2021年

Global Glaucoma Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 299635
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
青光眼治療藥的全球市場:2017年∼2021年 Global Glaucoma Therapeutics Market 2017-2021
出版日期: 2017年10月18日 內容資訊: 英文 97 Pages
簡介

所謂青光眼,是眼球內部的液體壓力增加的眼科疾病,如果不治療會喪失視力,也有失明的可能性。全球青光眼治療藥市場,預計2017∼2021年以3.81%的年複合成長率(CAGR)成長。

本報告提供全球的青光眼治療藥的市場相關分析,疾病概要(發病率等)治療藥的開發情形,全球整體的市場趨勢(今後5年的預測值),各類藥物、各地區的詳細趨勢,推動、市場的阻礙要素與其影響力,主要企業簡介,今後的市場機會等調查資料、考察,並將結果概述為以下內容。

第1章 摘要整理

第2章 市場分析技術

第3章 簡介

  • 市場趨勢的概要

第4章 市場環境

  • 市場概況
  • 波特的五力分析

第5章 開發平台(管線)現況

第6章 市場分析:各藥物等級

  • β- 阻斷劑
  • Alpha促效劑
  • 碳酸酐酵素抑制劑
  • 其他

第7章 各地區的分析

  • 地理區分
  • 各地區比較
  • 南北美洲市場
  • 歐洲、中東、非洲(EMEA)地區市場
  • 亞太地區市場

第8章 決策結構

第9章 促進市場成長的要素、課題

第10章 市場趨勢

第11章 供應商環境

  • 競爭方案

第12章 主要供應商分析

  • Allergan
  • Pfizer
  • Novartis
  • Merck
  • 其他著名的供應商

第13章 附錄

  • 簡稱集

圖表

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR15263

About Glaucoma Therapeutics

Glaucoma is an ophthalmic disorder that damages the optic nerves in the eyes. The disease is associated with elevated IOP and over time leads to the damage of the optic nerves, by destroying their cell bodies and delicate fibers. This can lead to partial loss of vision or complete blindness. Increased IOP is majorly due to the build-up of aqueous humor, which circulates in the front of an eye.

Technavio's analysts forecast the global glaucoma therapeutics market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global glaucoma therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Glaucoma Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Pfizer
  • Novartis
  • Merck

Other Prominent Vendors

  • Bayer HealthCare
  • Akorn
  • Bausch & Lomb
  • Santen Pharmaceutical
  • Teva Pharmaceutical
  • VISTAKON

Market driver

  • Increasing geriatric population leading to higher prevalence rate of glaucoma
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of alternative treatment options
  • For a full, detailed list, view our report

Market trend

  • Rising investment in R&D activities
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: RESEARCH METHODOLOGY

PART 03: INTRODUCTION

  • Market outline

PART 04: MARKET LANDSCAPE

  • Market overview
  • Five forces analysis

PART 05: PIPELINE LANDSCAPE

PART 06: MARKET SEGMENTATION BY DRUG CLASS

  • Global glaucoma therapeutics market by prostaglandin analogs
  • Global glaucoma therapeutics market by beta blockers
  • Global glaucoma therapeutics market by alpha agonists
  • Global glaucoma therapeutics market by carbonic anhydrase inhibitors
  • Global glaucoma therapeutics market by others

PART 07: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - market size and forecast
  • EMEA - market size and forecast
  • APAC - market size and forecast
  • Market opportunity

PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Competitive scenario

PART 12: KEY VENDOR ANALYSIS

  • Allergan
  • Pfizer
  • Novartis
  • Merck
  • Other prominent vendors

PART 13: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global ophthalmic disorder treatment market
  • Exhibit 02: Types of glaucoma
  • Exhibit 03: Factors leading to angle-closure glaucoma
  • Exhibit 04: Types of secondary glaucoma
  • Exhibit 05: Global glaucoma therapeutics market snapshot
  • Exhibit 06: Global glaucoma therapeutics market 2016-2021 ($ millions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Major pipeline molecules by vendors
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Global glaucoma therapeutics market by drug class ($ millions)
  • Exhibit 11: Global glaucoma therapeutics market by drug class 2016-2021
  • Exhibit 12: Global glaucoma therapeutics market by prostaglandin analogs 2016-2021 ($ millions)
  • Exhibit 13: Advantages and disadvantages of prostaglandin analogs present in global glaucoma therapeutics market
  • Exhibit 14: Global glaucoma therapeutics market by beta blockers 2016-2021 ($ millions)
  • Exhibit 15: Common beta blockers used as glaucoma therapeutics
  • Exhibit 16: Global glaucoma therapeutics market by alpha agonists 2016-2021 ($ millions)
  • Exhibit 17: Common alpha agonists used for glaucoma treatment
  • Exhibit 18: Global glaucoma therapeutics market by carbonic anhydrase inhibitors 2016-2021 ($ millions)
  • Exhibit 19: Common carbonic anhydrase inhibitors used for glaucoma treatment
  • Exhibit 20: Global glaucoma therapeutics market by others 2016-2021 ($ millions)
  • Exhibit 21: Cholinergic agents used for glaucoma treatment
  • Exhibit 22: Americas - market size and forecast
  • Exhibit 23: Regional comparison
  • Exhibit 24: Americas - market size and forecast
  • Exhibit 25: Americas - Year over year growth
  • Exhibit 26: A snapshot on eye diseases in US 2014 and 2030
  • Exhibit 27: Snapshot of economic and healthcare expenditure of US 2014-2015
  • Exhibit 28: Economic and healthcare snapshot of Canada
  • Exhibit 29: Top three countries in Americas
  • Exhibit 30: Economic and healthcare snapshot of Europe 2014
  • EMEA - market size and forecast
  • Exhibit 31: EMEA - year-over-year growth
  • Exhibit 32: Medication scenario for glaucoma in Europe
  • Exhibit 33: Top three countries in EMEA
  • Exhibit 34: APAC - market size and forecast
  • Exhibit 35: APAC - year-over-year growth
  • Exhibit 36: Top three countries in APAC
  • Exhibit 37: World population by age group 2015 and 2050
  • Exhibit 38: Percentage of population aged 60 and above by region 2015 and 2050
  • Exhibit 39: Non-therapeutic glaucoma treatment
  • Exhibit 40: Side effects of the commonly used glaucoma medications
  • Exhibit 41: Need of new drug delivery systems
  • Exhibit 42: Novel efforts in glaucoma therapeutics market
  • Exhibit 43: Competitive structure analysis of global glaucoma therapeutics market 2016
  • Exhibit 44: Allergan: Key highlights
  • Exhibit 45: Allergan: Strength assessment
  • Exhibit 46: Allergan: Strategy assessment
  • Exhibit 47: Allergan: Opportunity assessment
  • Exhibit 48: Pfizer: Key highlights
  • Exhibit 49: Pfizer: Strength assessment
  • Exhibit 50: Pfizer: Strategy assessment
  • Exhibit 51: Pfizer: Opportunity assessment
  • Exhibit 52: Novartis: Key highlights
  • Exhibit 53: Novartis: Strength assessment
  • Exhibit 54: Novartis: Strategy assessment
  • Exhibit 55: Novartis: Opportunity assessment
  • Exhibit 56: Merck: Key highlights
  • Exhibit 57: Merck: Strength assessment
  • Exhibit 58: Merck: Strategy assessment
  • Exhibit 59: Merck: Opportunity assessment
Back to Top